Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Sunday, Abivax Announces Late-Breaking Phase 3 Data Showing Obefazimod Achieved 16.4% Placebo-Adjusted Remission Rate At Week 8 In Ulcerative Colitis

Author: Benzinga Newsdesk | October 06, 2025 02:32am

50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2
ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapy
Obefazimod treatment was well tolerated with no new safety signals identified for both the 25mg and 50mg doses
Abivax to present a second late-breaking abstract on October 6. Management to host a conference call to discuss results of both late-breaking abstracts at 9am ET / 3pm CET on October 6.

Posted In: ABVX